Dive into immersive, case-based learning on evolving treatment strategies in multiple myeloma.

This augmented reality experience is designed for hematology/oncology clinicians and provides highly interactive exploration of real-world decision-making in relapsed/refractory multiple myeloma (RRMM). Through two detailed patient cases, learners examine treatment sequencing, bispecific antibody (BsAb) integration, and toxicity management in accordance with clinical practice guidelines. Simply launch the app and point your device at a flat surface to begin. The AR experience places engaging, expert-informed content directly into the learner’s environment, supporting dynamic and personalized knowledge retention.

What You’ll Learn:
- Evidence-based strategies for incorporating bispecific antibodies across multiple lines of therapy
- Clinical decision pathways for patients with standard-risk, high-risk, and frail disease profiles
- Key efficacy data for approved BCMA-directed therapies
- Safety considerations including cytokine release syndrome (CRS) recognition and management
- Insights into emerging bispecific antibody combinations and earlier-line clinical trials

Highlights:
- Two interactive patient cases simulating real-world RRMM presentations
- Step-by-step treatment journeys, from frontline therapy through triple class-exposed and penta-refractory relapse
- Animations highlighting mechanism-of-action visuals and immune-cell engagement
- Response assessments and toxicity monitoring
- Guideline-driven decision prompts with immediate feedback and rationale
- Designed for Oncology Professionals
- Ideal for hematologists/oncologists, advanced practice providers, and nurses seeking innovative, immersive CME learning experiences focused on MM treatment advances.
- Part of the ENCOMPASS Initiative

This app complements a full suite of digital education tools including VR modules, downloadable animations, and practice-support resources designed to improve patient-centered care and clinical outcomes.
Download now to explore the future of multiple myeloma care through cutting-edge augmented reality-based education.